Transcriptomic characterization reveals prognostic molecular signatures of sorafenib resistance in hepatocellular carcinoma

Sorafenib is the first-line treatment for patients with advanced unresectable hepatocellular carcinoma (HCC); however, only a small number of patients benefit from sorafenib, and many develop sorafenib resistance (SR) and severe side effects. To identify biomarkers for SR, we systematically analyzed...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Wei, Tao, Ran, Huang, Da, Yan, Weiming, Shen, Guanxin, Ning, Qin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7906139/
https://www.ncbi.nlm.nih.gov/pubmed/33495404
http://dx.doi.org/10.18632/aging.202365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7906139/
https://www.ncbi.nlm.nih.gov/pubmed/33495404
http://dx.doi.org/10.18632/aging.202365

Ejemplares similares